text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

Products > Featured Products >

Fluorescent Probe for Drugs-Human Serum Albumin (HSA) Binding Assay
―Powerful tool for drug discovery, R&D and metabolic toxicity assay―

Investigating whether drugs bind to Human Serum Albumin (HSA) and identifying the drug binding site on HSA are important for pharmacokinetics. BD140 (Product No. D4898), developed by Chang et al., is a novel fluorescent probe which binds to HSA drug binding site 2 specifically.1) BD140 is a useful tool to check whether drugs bind to HSA drug binding site 2.

Advantages

  • The binding of drugs to HSA drug binding site 2 is detectable.
  • Simple and quick assay can be performed.

Page Top

Application

[Assay condition]
  • Buffer: 1%DMSO in phosphate buffer (pH7.2 - 7.5)
  • HSA: 20 μM (50 μL/well)
  • Drugs: each concentration (50 μL/well)
  • BD140: 20 μM (50 μL/well)
  • Incubation: 20-25°C for 30 minutes
  • Measurement: plate-reader; excitation=365 nm, emission=585 nm
Binding of BD140 to HSA was not inhibited completely or nearly by warfarin and phenylbutazone, which bind to HSA drug binding site 1, in our result. On the other hand, binding of BD140 to HSA was inhibited sufficiently by ibuprofen, flurbiprofen and triiodobenzoic acid, which bind to drug binding site 2. Thus, BD140 is available for checking whether drugs bind to HSA drug binding site 2.

Page Top

Reference

Page Top

세션 상태
세션의 남은 시간은 10분입니다. 이대로 방치하면 세션이 끊어지고 탑페이지로 돌아갑니다. 같은 페이지에서 세션을 계속하려면 버튼을 클릭하십시오.분입니다. 이대로 방치하면 세션이 끊어지고 탑페이지로 돌아갑니다. 같은 페이지에서 세션을 계속하려면 버튼을 클릭하십시오.

세션이 시간 초과되었습니다. 탑페이지로 돌아갑니다.